Tagrisso, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, received its initial U.S. Food and Drug Administration (FDA) approval on November 13, 2015 [1]. This approval was for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for an EGFR mutation and who have experienced disease progression on or after platinum-based chemotherapy [1].
What other approvals has Tagrisso received?
Tagrisso has subsequently gained approval for expanded indications. In April 2017, the FDA approved Tagrisso for patients with metastatic NSCLC whose tumors have an EGFR exon 19 deletion or exon 21 (L858R) substitution mutation as detected by an FDA-approved test, who have progressed on or after prior chemotherapy [2]. Later, in April 2018, it was approved as a first-line treatment for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations [3]. Further expanded indications include the adjuvant treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations, after surgical resection [4].
When does Tagrisso's patent exclusivity expire?
Information regarding specific patent expiry dates for Tagrisso is best found through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can include details on patent grants, expiry dates, and any challenges [5].
How does Tagrisso work in treating lung cancer?
Tagrisso targets specific mutations in the EGFR gene that are commonly found in NSCLC [1]. By inhibiting these mutated EGFR proteins, Tagrisso prevents cancer cells from growing and dividing [1].
What are the main competitors to Tagrisso?
The competitive landscape for EGFR inhibitors in NSCLC is dynamic. Other drugs targeting EGFR mutations exist, and the development of next-generation inhibitors and other targeted therapies continually influences treatment options [6].
What clinical data supports Tagrisso's effectiveness?
Key clinical trials have demonstrated Tagrisso's efficacy across its approved indications. For instance, the monarch E study showed a significant benefit in adjuvant treatment [4]. The FLAURA trial established Tagrisso as a superior first-line treatment option compared to older EGFR inhibitors [3].
What are common side effects of Tagrisso?
Common side effects reported for Tagrisso include diarrhea, rash, dry skin, decreased appetite, and stomatitis [2]. More serious side effects can also occur [2].
What is the regulatory status of Tagrisso in other countries?
Tagrisso has received marketing authorization in numerous countries beyond the United States, reflecting its global significance in NSCLC treatment. Regulatory agencies in Europe, Japan, and other major markets have approved the drug for its various indications [3][4].
---
Sources
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[5] https://drugpatentwatch.com/
[6] https://www.cancer.gov/about-cancer/treatment/research/targeted-therapies